Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart

A Kinoshita1, H Urata, F M Bumpus

  • 1Department of Heart and Hypertension Research, Research Institute of the Cleveland Clinic Foundation, Ohio 44195-5069.

Insights

Human heart chymase efficiently forms angiotensin II (Ang II) by cleaving angiotensin I (Ang I). Its substrate specificity is defined by aromatic amino acids at P1 and proline at S2, guiding ideal substrate design.

Area of Science:

  • Biochemistry
  • Enzymology
  • Molecular Biology

Background:

  • Human heart chymase is a specific serine proteinase.
  • It efficiently generates angiotensin II (Ang II) from angiotensin I (Ang I).
  • Other chymases exhibit broader substrate specificity.

Purpose of the Study:

  • To define the substrate-binding site of human heart chymase.
  • To elucidate the enzyme's substrate specificity using Ang I analogs.

Main Methods:

  • Mapping the extended substrate-binding site of human heart chymase.
  • Utilizing Ang I analogs to probe enzyme-substrate interactions.

Main Results:

  • Human heart chymase prefers aromatic amino acids (phenylalanine, tyrosine, tryptophan) at the P1 site.
  • A significant preference for proline at the S2 subsite was observed.
  • Substrate hydrolysis is sensitive to amino acid deletions and leaving group length.

Conclusions:

  • Human heart chymase exhibits restricted substrate specificity compared to other chymases.
  • Ideal substrates contain a specific sequence: nXaa-Pro-[Phe, Tyr, or Trp]-Yaa-Yaa (n≥6).
  • This specificity is crucial for understanding Ang II formation and related physiological processes.

Related Concept Videos

Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
Introduction to Mechanisms of Enzyme Catalysis01:13

Introduction to Mechanisms of Enzyme Catalysis

For many years, scientists thought that enzyme-substrate binding took place in a simple "lock-and-key" fashion. This model stated that the enzyme and substrate fit together perfectly in one instantaneous step. However, current research supports a more refined view scientists call induced fit. The induced-fit model expands upon the lock-and-key model by describing a more dynamic interaction between enzyme and substrate. As the enzyme and substrate come together, their interaction causes a mild...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...